The Red Blood Cell Surface Defines a Distinct Tumor DNA Compartment for Liquid Biopsy
- 1Department of Medicine, Division of Pulmonary, Allergy and Critical Care, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104,
Abstract
Red blood cells (RBCs) modulate host inflammatory responses by scavenging mitochondrial and pathogen DNA. However, how RBC surface properties govern the capture of tumor-derived DNA remains poorly understood. We show that RBCs tether and retain tumor-derived DNA on their surface, forming a distinct circulating pool of RBC-bound tumor DNA (rtDNA). Desialylation increased DNA capture in a Toll-like receptor 9 (TLR9)-dependent manner, identifying RBC surface sialylation and TLR9 as a regulator of DNA binding. In mice bearing lung cancer xenografts, rtDNA was detected in all animals and its abundance correlated with tumor burden, whereas tumor DNA was undetectable in matched plasma samples. In patients with lung cancer, the majority of detected mutant tumor DNA was associated with RBCs rather than plasma, and RBC-derived mutations were concordant with molecular alterations identified in matched tumor tissue. Collectively, these findings establish the RBC surface as a tunable site of tumor-DNA capture and retention and challenge the plasma-centric paradigm of liquid biopsy by identifying a distinct cellular reservoir of tumor-derived genetic material.
Related
- Matched marrow and blood profiling reveals compartment- and feature-specific liquid-biopsy signals in multiple myeloma
- Multi-omics liquid biopsy identifies mitochondrial dysfunction in geographic atrophy and supports intraocular bioavailability of α-ketoglutarate
- Clinical translation of liquid biopsy in early cancer screening: biofluid selection, model construction, and clinical validation
- miRNAs bridging the gap between the tumor microenvironment and liquid biopsy in cutaneous melanoma
- Attitudes of cancer patients toward ctDNA-based liquid biopsy for follow-up.
BibTeX
@misc{elias2026blood,
title = {{The Red Blood Cell Surface Defines a Distinct Tumor DNA Compartment for Liquid Biopsy}},
author = {E. Elias and H. Ruger and J. Predina and B. A. Bleiberg and E. Noguera-Ortega and P. Areesawangkit and A. Kulkarni and J. C. Thompson and M. G. S. Shashaty and C. Langer and S. M. Albelda and N. S. Mangalmurti},
howpublished = {bioRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.07.755430},
url = {https://www.biorxiv.org/content/10.64898/2026.10.07.755430v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - The Red Blood Cell Surface Defines a Distinct Tumor DNA Compartment for Liquid Biopsy
AU - E. Elias
AU - H. Ruger
AU - J. Predina
AU - B. A. Bleiberg
AU - E. Noguera-Ortega
AU - P. Areesawangkit
AU - A. Kulkarni
AU - J. C. Thompson
AU - M. G. S. Shashaty
AU - C. Langer
AU - S. M. Albelda
AU - N. S. Mangalmurti
PY - 2026
DA - 2026/10/07
PB - bioRxiv
DO - 10.64898/2026.10.07.755430
UR - https://www.biorxiv.org/content/10.64898/2026.10.07.755430v1
AB - Red blood cells (RBCs) modulate host inflammatory responses by scavenging mitochondrial and pathogen DNA. However, how RBC surface properties govern the capture of tumor-derived DNA remains poorly understood. We show that RBCs tether and retain tumor-derived DNA on their surface, forming a distinct circulating pool of RBC-bound tumor DNA (rtDNA). Desialylation increased DNA capture in a Toll-like receptor 9 (TLR9)-dependent manner, identifying RBC surface sialylation and TLR9 as a regulator of DNA binding. In mice bearing lung cancer xenografts, rtDNA was detected in all animals and its abundance correlated with tumor burden, whereas tumor DNA was undetectable in matched plasma samples. In patients with lung cancer, the majority of detected mutant tumor DNA was associated with RBCs rather than plasma, and RBC-derived mutations were concordant with molecular alterations identified in matched tumor tissue. Collectively, these findings establish the RBC surface as a tunable site of tumor-DNA capture and retention and challenge the plasma-centric paradigm of liquid biopsy by identifying a distinct cellular reservoir of tumor-derived genetic material.
ER -